Saturday 17 October 2026
Export PHAT’s income statement to Excel — free account
Phathom Pharmaceuticals, Inc.
PHAT Healthcare Biotechnology
Phathom Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $175.1 million, up 216.9% from fiscal 2024. In the quarter to June 2026, revenue grew 88.0%, EPS grew 80.0%, free cash flow grew 96.9% and total debt fell 19.8%, each against the same quarter a year earlier.
6.92
0.58
−7.73%
Follow PHAT
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 4 |
P/E ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 0.00 | 9.28 | 6.91 |
Altman Z-Score |
— | — | — | — | — | — | (2.86) | (5.59) | (7.89) |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | — | (4.50) | (11.48) | (21.03) |
Beneish M-Score |
— | — | — | — | — | — | — | 67.35 | (1.39) |
P/Operating CF |
— | — | — | — | — | — | (10.74) | (8.08) | (241.90) |
P/B ratio |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | — | 0.00 | 7.74 | 7.42 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (1.72) | (1.60) | (7.79) |
EV/FCF |
— | — | — | — | — | — | (1.70) | (1.60) | (7.78) |
Quick Ratio |
— | 0.40 | 65.04 | 5.18 | 9.69 | 5.92 | 9.88 | 3.92 | 1.58 |
Current Ratio |
— | 0.41 | 68.20 | 5.25 | 9.86 | 6.12 | 10.25 | 4.20 | 1.73 |
Net Debt/EBITDA |
— | (0.87) | 2.09 | 1.94 | 0.71 | 0.35 | 1.48 | 0.35 | (0.51) |
Debt/Assets |
0.00% | 216.19% | 8.92% | 15.92% | 47.34% | 57.80% | 33.31% | 53.24% | 80.68% |
Debt/Equity |
— | (1.52) | 0.10 | 0.24 | 1.24 | (1.27) | (1.89) | (0.79) | (0.48) |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.55 |
Operating CF/Net income |
— | 0.79 | 0.14 | 0.54 | 1.03 | 0.74 | 0.68 | 0.80 | 0.75 |
Capex/Depreciation |
— | — | (60.55) | (0.65) | (0.08) | (0.38) | (0.67) | (0.05) | (0.06) |
Interest Coverage |
— | (94.23) | (25.43) | (27.43) | (19.90) | (6.32) | (3.99) | (3.85) | (2.35) |
| — | (1.14%) | (225.11%) | (61.14%) | (108.01%) | 14,877.58% | 273.21% | 204.89% | 63.97% | |
| — | (285.59%) | (197.71%) | (46.74%) | (59.39%) | (111.63%) | (69.68%) | (84.41%) | (69.41%) | |
ROIC |
— | 0.00% | (931.32%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | 100.16% | (101.12%) | (54.50%) | (85.51%) | (145.94%) | (55.87%) | (121.18%) | (225.78%) |
Average Days of Receivables |
— | — | — | — | — | — | 876.11 | 256.30 | 162.85 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 7,316.57% | 61.68% | 18.72% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 17,291.50% | 526.07% | 159.74% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6,601.91% | 43.52% | 16.40% |
Graham Net Nets |
— | — | — | — | — | — | (0.19) | (0.53) | (0.39) |
Graham Number |
— | — | — | — | — | — | 11.13 | 21.98 | 20.34 |
Earnings Yield |
— | — | — | — | — | — | (42.31%) | (65.89%) | (18.44%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (29.60%) | (52.03%) | (13.81%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.87 | 2.40 |
Operating CF per Share |
— | (0.17) | (3.21) | (2.10) | (4.01) | (3.75) | (2.68) | (4.22) | (2.29) |
Capex per Share |
— | 0.00 | (2.22) | (0.03) | (0.01) | (0.03) | (0.03) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.17) | (5.43) | (2.13) | (4.02) | (3.77) | (2.71) | (4.22) | (2.29) |
Cash per Share |
— | 0.15 | 21.45 | 8.65 | 4.95 | 3.97 | 7.44 | 4.71 | 1.78 |
Shareholders Equity per Share |
— | (0.21) | 20.05 | 5.85 | 1.95 | (1.91) | (1.42) | (4.01) | (6.01) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.21) | 20.05 | 5.85 | 1.95 | (1.91) | (1.42) | (4.01) | (6.01) |
Free Cash Flow |
— | (1.02) | (61.76) | (70.73) | (148.78) | (147.57) | (139.21) | (266.90) | (167.00) |
Working Capital |
— | (1.29) | 251.85 | 235.84 | 167.61 | 134.28 | 358.65 | 274.41 | 96.93 |
Capital Expenditures |
— | — | (25.25) | (1.04) | (0.33) | (1.04) | (1.63) | (0.13) | (0.23) |
Net Current Asset Value |
— | (1.29) | 226.38 | 190.53 | 69.25 | (79.11) | (89.17) | (271.76) | (468.35) |
EV/EBIT |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 2.40 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | — | 0.90 | 1.62 | 6.33 | 2.26 | 1.14 | 2.02 | 3.43 |
Cash ROIC |
— | (66.30%) | (12.49%) | (13.38%) | (43.12%) | (83.93%) | (31.18%) | (108.90%) | 168.50% |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | 2.73 | 3.00 |
Accounts Payable Turnover |
— | 0.00 | 0.02 | 0.03 | 0.05 | 0.08 | 0.01 | 0.69 | 2.92 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.61 | 5.18 |
Average Days of Payables |
— | 0.00 | 31,891.88 | 20,418.10 | 3,607.97 | 5,885.33 | 27,541.11 | 481.01 | 80.48 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 2,640.24 | 146.86 | 89.12 |
Average Receivables |
— | — | — | — | — | — | — | 20.22 | 58.46 |
Average Payables |
— | 0.38 | 0.38 | 8.74 | 10.97 | 7.57 | 11.30 | 11.55 | 7.75 |
Average Inventory |
— | — | — | — | — | — | — | 2.21 | 4.36 |
Average Assets |
— | 0.45 | 129.04 | 276.14 | 242.27 | 177.12 | 289.33 | 396.08 | 318.73 |
Average Common Equity |
— | 113.33 | 113.33 | 211.11 | 133.21 | (1.33) | (73.79) | (163.17) | (345.87) |
Columns are period end dates